Fog; Karina

Patent Applications and Registrations

Patent applications and USPTO patent grants for Fog; Karina.The latest application filed is for "agents, uses and methods for the treatment of synucleinopathy".

Company Profile

17.11.14

Fog; Karina - Valby DK

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Agents, uses and methods for the treatment of synucleinopathy Grant 11,421,024 - Kallunki , et al. August 23, 2	2022-08-23
Alpha-synuclein antibodies Grant 11,325,968 - Kallunki , et al. May 10, 2	2022-05-10
Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210147522 - KALLUNKI; Pekka ; et al.	2021-05-20
Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210061892 - KALLUNKI; Pekka ; et al.	2021-03-04
Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210054057 - KALLUNKI; Pekka ; et al.	2021-02-25
Agents, uses and methods for the treatment of synucleinopathy Grant 10,800,836 - Kallunki , et al. October 13, 2	2020-10-13
Assay, Method And Treatment Of Alpha-synucleinopathies App 20200309796 - Malik; Ibrahim John ; et al.	2020-10-01
Agents, uses and methods for the treatment of synucleinopathy Grant 10,647,763 - Kallunki , et al.	2020-05-12
Agents, uses and methods for the treatment of synucleinopathy Grant 10,647,764 - Kallunki , et al.	2020-05-12
Agents, uses and methods for the treatment of synucleinopathy Grant 10,640,554 - Kallunki , et al.	2020-05-05
Agents, Uses And Methods App 20200024337 - Kallunki; Pekka ; et al.	2020-01-23
Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190382473 - KALLUNKI; Pekka ; et al.	2019-12-19
Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190367595 - Kallunki; Pekka ; et al.	2019-12-05
Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190367594 - KALLUNKI; Pekka ; et al.	2019-12-05
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation Grant 10,364,286 - Fog , et al.	2019-07-30
Antibodies for the treatment of synucleinopathy Grant 10,364,285 - Kallunki , et al.	2019-07-30
Antibodies for the treatment of synucleinopathy Grant 10,358,483 - Kallunki , et al. July 23, 2	2019-07-23
Antibodies for the treatment of synucleinopathy Grant 10,358,484 - Kallunki , et al. July 23, 2	2019-07-23
Antibodies for the treatment of synucleinopathy Grant 10,358,482 - Kallunki , et al.	2019-07-23
Monoclonal Anti-alpha-synuclein Antibodies For Preventing Tau Aggregation App 20180179273 - Fog; Karina ; et al.	2018-06-28
Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180179271 - Kallunki; Pekka ; et al.	2018-06-28
Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180179270 - Kallunki; Pekka ; et al.	2018-06-28
Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180127492 - Kallunki; Pekka ; et al.	2018-05-10
Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180127491 - Kallunki; Pekka ; et al.	2018-05-10
Agents, Uses and Methods for the Treatment of Synucleinopathy App 20170015739 - Kallunki; Pekka ; et al.	2017-01-19

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.